Literature DB >> 10923919

Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver.

K Washington1, K Wright, Y Shyr, E B Hunter, S Olson, D S Raiford.   

Abstract

Factors associated with the development of fibrosis in nonalcoholic steatohepatitis (NASH) are largely unknown, although an association with increased hepatic iron has been suggested. Hepatic stellate cells are the principal collagen-producing cells in many liver diseases and when activated express alpha-smooth muscle actin (alpha-SMA). Hepatic stellate cell activation and association with fibrosis, necroinflammatory activity, steatosis, and stainable iron in 60 cases of NASH and 16 cases of steatosis were evaluated. All 76 patients were obese or had other risk factors for NASH. All biopsy specimens were stained for alpha-smooth muscle actin to evaluate the pattern of hepatic stellate cell activation and were evaluated for inflammatory activity (0 to 3), fibrosis (0 to 4), and stainable iron stores (0 to 4). The zonal location of activated stellate cells was recorded, and the degree of activation was graded as high-grade or low-grade based on the percentage of lobular alpha-SMA+ cells. Activated stellate cells were identified in the hepatic lobule in 74 of 76 biopsy specimens and graded as low-grade in 26 and high-grade in 48. Zone 3 was involved in 72 of 74 positive cases, and in 33 cases, the activated stellate cells were preferentially located in zone 3. The degree of stellate cell activation correlated with fibrosis but not with inflammatory activity, severity of steatosis, or stainable iron. In most cases, the degree of stellate cell activation paralleled the degree of hepatic fibrosis, but in 25 cases, the degree of hepatic stellate cell activation was greater than expected, raising the question of whether such patients are at risk for disease progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923919     DOI: 10.1053/hupa.2000.8440

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  28 in total

Review 1.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

2.  Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis.

Authors:  Shiro Yokohama; Yoshihiko Tokusashi; Kimihide Nakamura; Yosui Tamaki; Satoshi Okamoto; Mituyoshi Okada; Kazunobu Aso; Takenao Hasegawa; Masaru Aoshima; Naoyuki Miyokawa; Masakazu Haneda; Masashi Yoneda
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

3.  A retinoic acid receptor β2 agonist reduces hepatic stellate cell activation in nonalcoholic fatty liver disease.

Authors:  Steven E Trasino; Xiao-Han Tang; Jose Jessurun; Lorraine J Gudas
Journal:  J Mol Med (Berl)       Date:  2016-06-06       Impact factor: 4.599

Review 4.  Evolving pathophysiologic concepts in nonalcoholic steatohepatitis.

Authors:  Brent A Neuschwander-Tetri
Journal:  Curr Gastroenterol Rep       Date:  2002-02

5.  A glass-based, continuously zonated and vascularized human liver acinus microphysiological system (vLAMPS) designed for experimental modeling of diseases and ADME/TOX.

Authors:  Xiang Li; Subin M George; Lawrence Vernetti; Albert H Gough; D Lansing Taylor
Journal:  Lab Chip       Date:  2018-08-21       Impact factor: 6.799

Review 6.  Biliverdin reductase and bilirubin in hepatic disease.

Authors:  Lauren Weaver; Abdul-Rizaq Hamoud; David E Stec; Terry D Hinds
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-01       Impact factor: 4.052

7.  Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in mice.

Authors:  Ke-Yong Wang; Akihide Tanimoto; Sohsuke Yamada; Xin Guo; Yan Ding; Teruo Watanabe; Takeshi Watanabe; Kimitoshi Kohno; Ken-Ichi Hirano; Hideo Tsukada; Yasuyuki Sasaguri
Journal:  Am J Pathol       Date:  2010-06-21       Impact factor: 4.307

8.  The role of iNOS in cholesterol-induced liver fibrosis.

Authors:  Sarit Anavi; Michal Eisenberg-Bord; Michal Hahn-Obercyger; Olga Genin; Mark Pines; Oren Tirosh
Journal:  Lab Invest       Date:  2015-06-22       Impact factor: 5.662

Review 9.  Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance.

Authors:  Yutaka Kohgo; Katsuya Ikuta; Takaaki Ohtake; Yoshihiro Torimoto; Junji Kato
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

10.  NHE1 deficiency in liver: implications for non-alcoholic fatty liver disease.

Authors:  Vikram Prasad; Shivani Chirra; Rohit Kohli; Gary E Shull
Journal:  Biochem Biophys Res Commun       Date:  2014-06-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.